Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid Marihuana Extract Marihuana	2010 7350 7360	 

The company plans to import finished dosage unit products containing gammahydroxybutryic acid and cannabis extracts for clinical trial studies.

These cannabis extracts compounds are listed under drug code 7350. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: September 11, 2017.

#### Demetra Ashley,

Acting Assistant Administrator. [FR Doc. 2017–19833 Filed 9–15–17; 8:45 am]

BILLING CODE 4410-09-P

#### **DEPARTMENT OF JUSTICE**

## Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Specgx LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before November 17, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of

the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on August 9, 2017, Specgx LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	2010	I
Tetrahydrocannabinols	7370	1
Codeine-N-oxide	9053	1
Dihydromorphine	9145	1
Difenoxin	9168	1
Morphine-N-oxide	9307	1
Normorphine	9313	1
Norlevorphanol	9634	1
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821	1
Butyryl Fentanyl	9822	1
Amphetamine	1100	П
Methamphetamine	1105	П
isdexamfetamine	1205	П
Methylphenidate	1724	П
Nabilone	7379	l ii
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	l ii
Codeine	9050	l ii
Dihydrocodeine	9120	ii
Oxycodone	9143	ii
Hydromorphone	9150	ii
Diphenoxylate	9170	l ii
Ecgonine	9180	l ii
Hydrocodone	9193	l ii
_evorphanol	9220	l ii
Meperidine	9230	ii
Vethadone	9250	l ii
Methadone intermediate	9254	l ii
Dextropropoxyphene, bulk (non-dosage forms)	9273	
Morphine	9300	l ii
Oripavine	9330	l ii
Thebaine	9333	l ii
Opium tincture	9630	II
Opium, powdered	9639	l ii
Oxymorphone	9652	l ii
Noroxymorphone	9668	l ii
Alfentanil	9737	ii
Remifentanil	9739	l ii
Sufentanil	9740	l ii
Tapentadol	9780	ii
Fentanyl	9801	l ii

The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers.

Dated: September 13, 2017

#### Demetra Ashley,

Acting Assistant Administrator. [FR Doc. 2017–19786 Filed 9–15–17; 8:45 am]

BILLING CODE 4410-09-P

#### **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

[Docket No. DEA-392]

Importer of Controlled Substances Application: Specgx LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before October 18, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before October 18, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant

Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on August 9, 2017, Specgx LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana	7360 8501 9040 9600 9670	          

The company plans to import the listed controlled substances to bulk manufacture into Active Pharmaceutical Ingredients for distribution to its customers. In reference to drug code 7360 (marihuana) the company plans to import a synthetic cannabidiol. No other activity for this drug code is authorized for this registration. Placement of these drug codes onto the company's registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: September 11, 2017.

#### Demetra Ashley,

Acting Assistant Administrator. [FR Doc. 2017–19784 Filed 9–15–17; 8:45 am]

BILLING CODE 4410-09-P

#### **DEPARTMENT OF JUSTICE**

### **Drug Enforcement Administration**

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Halo Pharmaceutical, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before November 17, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 11, 2017, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany, New Jersey 07981 applied to be registered as a bulk manufacturer the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Dihydromorphine	9145	I
Hydromorphone	9150	II

The company plans to manufacture Hydromorphone (9150) for distribution to its customers. Dihydromorphine (9145) is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution.

Dated: September 11, 2017.

### Demetra Ashley,

Acting Assistant Administrator.

[FR Doc. 2017–19834 Filed 9–15–17; 8:45 am]

BILLING CODE P

#### **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-392]

Importer of Controlled Substances Application: Unither Manufacturing LI C

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before October 18, 2017. Such persons may also file a written request